MENU
+Compare
XXII
Stock ticker: NASDAQ
AS OF
Sep 12 closing price
Price
$1.80
Change
-$0.00 (-0.00%)
Capitalization
6.81M

XXII 22nd Century Group Inc Forecast, Technical & Fundamental Analysis

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis... Show more

Industry: #Miscellaneous
XXII
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XXII with price predictions
Sep 12, 2025

XXII sees its Stochastic Oscillator climbs out of oversold territory

On September 11, 2025, the Stochastic Oscillator for XXII moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XXII's RSI Indicator exited the oversold zone, of 56 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 12, 2025. You may want to consider a long position or call options on XXII as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

XXII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XXII declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XXII entered a downward trend on September 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.209) is normal, around the industry mean (6.877). XXII has a moderately low P/E Ratio (0.001) as compared to the industry average of (24.565). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.974). XXII has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.049). P/S Ratio (0.013) is also within normal values, averaging (2.574).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock worse than average.

View a ticker or compare two or three
XXII
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a plant biotechnology company

Industry Tobacco

Profile
Fundamentals
Details
Industry
Miscellaneous
Address
321 Farmington Road
Phone
+1 716 270-1523
Employees
64
Web
https://www.xxiicentury.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARQQ33.713.46
+11.42%
Arqit Quantum Inc
SOL1.880.02
+1.08%
Emeren Group Ltd
TSLX24.670.01
+0.04%
Sixth Street Specialty Lending
APG34.88-0.73
-2.05%
APi Group Corporation
YCBD0.68-0.02
-2.72%
CBDMD Inc

XXII and Stocks

Correlation & Price change

A.I.dvisor tells us that XXII and UVV have been poorly correlated (+16% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XXII and UVV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XXII
1D Price
Change %
XXII100%
N/A
UVV - XXII
16%
Poorly correlated
-1.23%
TPB - XXII
11%
Poorly correlated
+1.65%
RLX - XXII
11%
Poorly correlated
-2.61%
KAVL - XXII
7%
Poorly correlated
-1.74%
MO - XXII
5%
Poorly correlated
+0.44%
More